新型饱和脂肪酸胆酸缀合物的合成及抗胆结石活性研究

胆结石是常见多发病, 但临床缺乏有效的治疗药物. 饱和脂肪酸与胆酸的缀合物能有效预防胆固醇结晶、溶解体内胆固醇结石. 以胆酸或熊去氧胆酸24位羧基为连接位点, 以氨基酸为连接子, 通过酰胺键将载体与具有溶石活性的饱和脂肪酸偶联, 设计合成了一系列新型脂肪酸胆酸缀合物, 其结构经元素分析, IR, 1H NMR和MS光谱分析确证. 通过测定化合物对模型胆汁溶液胆固醇结晶及模型小鼠胆结石的溶解活性, 研究了其体内外溶石活性.     

电荷翻转型药物载体用于肿瘤细胞核靶向药物输送的研究

大多数的抗癌药物属于DNA毒化物,它们只有作用于细胞核中的DNA或与之相关的酶才能发挥药效。但是,癌细胞先天和后天获得的耐药机制能够有效地限制抗癌药物进入细胞核。目前研制的大多数药物载体只靶向细胞中的溶酶体、不能进入细胞核。最近,β-羧基酰胺化的阳离子聚合物如聚乙烯亚胺(PEI)和聚L-赖氨酸(PLL)被发展为从负电向正电翻转的新型细胞核靶向的药物载体,用于将药物直接输送到癌细胞的细胞核中,从而使药物避开肿瘤细胞膜及细胞浆中的多种耐药机制。在生理环境中,β-羧基酰胺化的阳离子聚合物带负电荷,抑制了阳离子聚合物与血液中蛋白质及细胞之间的非特异性相互作用。而当载体被癌细胞内吞并进入其酸性的溶酶体后,β-羧基酰胺键很快水解为胺基,载体又变为带正电荷,使载体能够逃离溶酶体并进入细胞核,将药物释放到细胞核中。实验结果表明,肿瘤靶向电荷翻转型药物载体能够有效地将药物输送到细胞核中,从而使药物避开癌细胞的耐药机制,提高药物疗效。本文就电荷翻转药物载体的进展做了简述。     

叶酸修饰碳纳米管的合成及其负载伊立替康的释放

以叶酸改性壳聚糖修饰的碳纳米管为药物载体,选用治疗结肠癌的抗癌药物伊立替康为模型药物,通过非共价包覆的方式制备具有靶向功能的碳纳米管基药物载体材料。采用FT—IR、UV和TGA等对各阶段产物进行表征,考察了纳米载体的载药率和药物体外释放性能。结果表明,模型药物成功加载到了功能化的碳纳米管上,其栽药量达63．6％,包封率为85．92％。体外释放实验显示靶向功能化碳纳米管对伊立替康具有缓释作用,药物在37℃,pH-7．4的PBS缓冲溶液中能持续释放70h以上。     

用于基因和药物传递的多肽及聚多肽材料

多肽和聚多肽作为一类新型的生物医用材料,由于其具有良好的生物活性、生物可降解性以及生物相容性而备受瞩目.将具有特殊生理功能的多肽作为基因或药物载体、或用于药物修饰等,可以提高基因转染效率,增强药物的靶向治疗效果,降低药物的毒副作用.本文综述了近年来多肽及聚多肽材料在这些生物医学领域的应用及进展,对部分活性肽的作用机制和...     

DNA纳米结构在药物转运载体和智能载药中的应用进展

纳米材料具有荷载效率高、靶向性能好、半衰期较长等优点, 非常适于作为药物转运载体, 可有效提高药物的水溶性、稳定性和疾病治疗效果.目前, 开发具有良好生物相容性、可控靶向释放能力和精确载药位点的理想药物转运载体, 仍是该领域存在的挑战性问题和当前研究的重点.自组装DNA纳米结构是一类具有精确结构、功能多样的纳米生物材料, 具有良好的生物相容性和稳定性、较高的膜渗透性和可控靶向释放能力等优点, 是理想的药物转运载体和智能载药材料.本文总结了DNA纳米结构的发展历程、DNA纳米结构作为药物转运载体的研究现状、动态DNA纳米结构在智能载药中的应用进展, 并对其发展前景进行了展望.     

TLC—UV分光光度法测定熊胆主要成分的研究

熊胆为名贵中药,有健胃、镇痉、镇痛等作用,其特有成分是熊去氧胆酸(UDCA),此外尚含鹅去氧胆酸(CDCA),去氧胆酸(DCA)及胆酸(CA)等胆汁酸,UDCA与CDCA为立体异构体。有关商品熊胆胆汁酸成分的定性鉴别及薄层扫描法测定熊胆中熊去氧胆酸含量已有报导。宇治昭用气相色谱法火焰离子检测器和薄层自动检测器测定了熊胆中结合     

牛磺熊去氧胆酸的合成研究

以熊去氧胆酸为原料，先与氯甲酸乙酯形成混酐，再与牛磺酸反应合成牛磺熊去氧胆酸。通优化反应条件、简化后处理等工艺改进，提高了收率，得到了较高纯度的结晶产品。     

端基为肝靶向基团的聚谷氨酸苄酯的合成及表征

本文研究甘草次酸、 甘草酸和胆酸的二胺类衍生物的合成及其引发谷氨酸苄酯-N-羧酸酐的开环聚合, 合成了在端基具有不同肝靶向识别基团的聚谷氨酸苄酯. 该材料可能具有肝细胞主动靶向作用, 为进一步的肝靶向药物控释的研究奠定了基础.     

猪去氧胆酸化学 III: 猪去氧胆酸转变成鹅去氧胆酸和熊去氧胆酸

在从猪去氧胆酸合成熊去氧胆酸和鹅去氧胆酸时, 其关键是在羟基移位的一系列反应中保留5β构型. 本文报导了应用1,2-酮基移位反应, 实现上述转化的过程.     

微米及纳米非球形聚合物粒子的制备方法

具有精确形状的聚合物粒子已经被广泛应用到各个研究领域,尤其是在设计新型载药系统时,微米或纳米非球形聚合物粒子在药物释放、体内传输、循环、靶向能力、被巨噬细胞内吞的速率以及细胞膜上的黏附作用等多方面都比相应的球形粒子表现出更加明显的优越性.因此能够制备出特定形状的非球形粒子作为药物载体可以提高综合疗效.但是,目前在微米或...     

Novel liver-specific nitric oxide（NO） releasing drugs with bile acid as both NO carrier and targeting ligand

Novel liver-specific nitric oxide（NO） releasing drugs with bile acid as both the NO carrier and targeting ligand were designed and synthesized by direct nitration of the hydroxyl group in bile acids or the 3-Ohydroxyl alkyl derivatives,with the intact 24-COOH being preserved for hepatocyte specific recognition.Preliminary biological evaluation revealed that oral administrated targeted conjugates could protect mice against acute liver damage induced by acetaminophen or carbon tetrachloride.The nitrate level in the liver significantly increased after oral administration of 1e while nitrate level in the blood did not significantly change.Co-administration of ursodeoxycholic acid（UDCA） significantly antagonized the increase of nitrate in the liver resulted by administration of 1e.     

Novel NO-releasing derivatives of betulinic acid with antitumor activity

Thirteen novel NO-releasing derivatives of betulinic acid (BA) bearing two types of NO-donors (nitrates and furoxans) were synthesized and evaluated for their antitumor activity. The results showed that furoxan-based derivatives exhibited higher antitumor activity than nitrate-based derivatives, with compounds 11a and 11b displaying promising potency against B16 cell lines and HepG2 cell lines (IC50 < 1 μmol/L). Wesupposed that NO-releasing amount of these derivatives which can be detected by Griess method may contribute more to their antitumor activity. As a result, furoxan-based derivatives released larger amount of NO than that of nitrate-based derivatives, which partially explained the higher anti-tumor activity of the former.     

肝靶向海藻酸钠载药纳米粒的细胞毒性研究

本研究将具有肝靶向性分子甘草次酸（GA）偶联在具有生物相容性和生物可降解性的天然高分子海藻酸钠（ALG）上,合成了甘草次酸改性的海藻酸钠（GA—ALG）;对广谱抗癌药物阿霉素（DOX）进行包封,制备了肝靶向载药纳米粒,并考察了GA—ALG载药纳米粒的体外释药性能和对肝癌细胞的抑制作用．利用核磁、红外和元素分析技术对GA—ALG结构和GA取代度进行了表征;对GA—ALG载药纳米粒的形貌、粒径、表面Zeta电位等进行了测定,结果显示纳米粒具有较规则球形结构,其水合粒径为（214±11）nm．GA—ALG载药纳米粒在模拟生理条件下（pH7．4）可持续释药长达20天;MTT结果显示GA-ALG载药纳米粒对7703肝癌细胞的具有明显的杀伤作用．     

Recent Developments in Nitric Oxide Donors and Delivery for Antimicrobial and Anti-Biofilm Applications

The use of nitric oxide (NO) is emerging as a promising, novel approach for the treatment of antibiotic resistant bacteria and biofilm infections. Depending on the concentration, NO can induce biofilm dispersal, increase bacteria susceptibility to antibiotic treatment, and induce cell damage or cell death via the formation of reactive oxygen or reactive nitrogen species. The use of NO is, however, limited by its reactivity, which can affect NO delivery to its target site and result in off-target effects. To overcome these issues, and enable spatial or temporal control over NO release, various strategies for the design of NO-releasing materials, including the incorporation of photo-activable, charge-switchable, or bacteria-targeting groups, have been developed. Other strategies have focused on increased NO storage and delivery by encapsulation or conjugation of NO donors within a single polymeric framework. This review compiles recent developments in NO drugs and NO-releasing materials designed for applications in antimicrobial or anti-biofilm treatment and discusses limitations and variability in biological responses in response to the use of NO for bacterial eradiation.     

Ionizable Amphiphilic Dendrimer‐Based Nanomaterials with Alkyl‐Chain‐Substituted Amines for Tunable siRNA Delivery to the Liver Endothelium In Vivo

A library of dendrimers was synthesized and optimized for targeted small interfering RNA (siRNA) delivery to different cell subpopulations within the liver. Using a combinatorial approach, a library of these nanoparticle‐forming materials was produced wherein the free amines on multigenerational poly(amido amine) and poly(propylenimine) dendrimers were substituted with alkyl chains of increasing length, and evaluated for their ability to deliver siRNA to liver cell subpopulations. Interestingly, two lead delivery materials could be formulated in a manner to alter their tissue tropism within the liver—with formulations from the same material capable of preferentially delivering siRNA to 1) endothelial cells, 2) endothelial cells and hepatocytes, or 3) endothelial cells, hepatocytes, and tumor cells in vivo. The ability to broaden or narrow the cellular destination of siRNA within the liver may provide a useful tool to address a range of liver diseases.     

Nitric oxide release: part I. Macromolecular scaffolds

The roles of nitric oxide (NO) in physiology and pathophysiology merit the use of NO as a therapeutic for certain biomedical applications. Unfortunately, limited NO payloads, too rapid NO release, and the lack of targeted NO delivery have hindered the clinical utility of NO gas and low molecular weight NO donor compounds. A wide-variety of NO-releasing macromolecular scaffolds has thus been developed to improve NO's pharmacological potential. In this tutorial review, we provide an overview of the most promising NO release scaffolds including protein, organic, inorganic, and hybrid organic-inorganic systems. The NO release vehicles selected for discussion were chosen based on their enhanced NO storage, tunable NO release characteristics, and potential as therapeutics.     

Facile construction of multivalent targeted drug delivery system from Boltorn® series hyperbranched aliphatic polyester and folic acid

The conjugation of PAMAM dendrimer and folic acid is a well‐studied multivalent targeted drug delivery system, but it is expensive and difficult to be synthesized. To construct an inexpensive and well‐defined multivalent targeted drug delivery system, a cheap carrier — Boltorn® series hyperbranched aliphatic polyester — was proposed as the nanodevice to carry fluorescein, folic acid, and methotrexate. The construction follows a facile route: (1) synthesizing the carrier — a hybrid hyperbranched polymer with acyclic hydroxyls and cyclic carbonate, (2) linking fluorescein to the hyperbranched polymer via the acyclic hydroxyls, (3) opening the ring of the cyclic carbonate with the amino group of folic acid, and (4) attaching the drug methotrexate to the resulting hydroxyls by ring‐opening reaction. In this route, the peripheral hydroxyls of the hyperbranched polymer are divided into two groups and reacted with three reagents in sequence to form the desired multivalent targeted drug delivery system. Copyright © 2009 John Wiley & Sons, Ltd.     

叶酸高分子纳米胶束在小鼠体内的靶向分布

合成了带有叶酸靶向和荧光染料的聚合物FA-PEG-PLA和mPEG-b-P（LA-co-MHC／NIR）,通过混合胶束的方法制备近红外染料胶束P（NIR）（含染料NIR6％）,叶酸胶束FA-P（NIR）1（含染料NIR5．4％,叶酸LFA0．5％）和叶酸胶束FA-P（NIR）2（含染料NIR4．8％,叶酸FA0．9％）;建立了H22肝癌小鼠模型,考察了高分子纳米胶束及叶酸靶向纳米胶束在H22肝癌小鼠体内分布．结果表明,高分子纳米胶束及叶酸靶向纳米胶束在小鼠体内分布都具有时间相关性,无叶酸配体的高分子纳米胶束在尾静脉注射24h后在肿瘤部位有少量聚集,大部分胶束在肝部聚集,30h内大部分已被排泄系统排出体外;含有叶酸配体的纳米胶束在尾静脉注射后6-30h内在肿瘤部位有明显的聚集,其中,FA-P（NIR）1胶束在肿瘤和肝部位的聚集相当,FA-P（NIR）2胶束在静脉注射24h后在肿瘤聚集明显高于肝部．带有叶酸配体的高分子纳米胶束相对于不带叶酸配体的纳米胶束在小鼠肿瘤部位具有明显的聚集,并且随着叶酸含量的增大,聚集效果更明显．     

肝组织特异性非离子型高分子磁共振造影剂的制备及性能评价

L-酪氨酸甲酯与DTPA双N-羟基琥珀酰亚胺活性酯(SuO-DTPA-OSu)反应,合成了含L-酪氨酸甲酯残基的DTPA单N-羟基琥珀酰亚胺活性酯(SuO-DTPA-Tyr).以EDC/NHS为媒介,通过一步反应将不同量的乳糖酸偶联到α,β-聚[(2-氨乙基)-L-天冬酰胺]上,然后将含有苯环的结构的SuO-DTPA-Tyr与联有D-半乳糖的α,β-聚[(2-氨乙基)-L-天冬酰胺]反应,合成了3种含糖量不同的大分子配体,并制备了其Gd(III)螯合物.结果表明,EDC/NHS方法操作简便,产率高且易于提纯;而SuO-DTPA-Tyr上L-酪氨酸甲酯残基的引入,不仅实现了高分子造影剂的非离子化,同时L-酪氨酸甲酯残基上的苯环结构也可以方便核磁氢谱的指认.大分子配体的细胞毒性随含糖量降低而增加,但均小于同浓度聚(L-赖氨酸)的毒性;大分子螯合物的细胞毒性与商用小分子造影剂的细胞毒性相当,但其弛豫率明显高于小分子造影剂的弛豫率;大分子螯合物在小白鼠肝部有比商用小分子造影剂(钆喷酸葡胺)更好的成像增强效果及更长的停留时间,且在注射后前6h,含D-半乳糖酸残基的大分子螯合物比不含D-半乳糖酸残基的大分子螯合物在小白鼠肝部的代谢速率慢,并呈现出更清晰的造影效果.     

Production of Bioactive Substances to Alleviates Hangover and Ethanol-Induced Liver Damage through Fermentation of Oenanthe javanica Using Lactiplantibacillus plantarum

The purpose of this study is to evaluate the effect of the bioconversion products of Oenanthe javanica extract fermented by Lactiplantibacillus plantarum (OEFL) on relieving hangovers and improving liver function. In addition, the bioactive substance of the OEFL, which alleviates hangover and ethanol-induced liver damage, was identified and its bioactive property was verified through in vivo experiments. In major substances analysis using high-performance liquid chromatography, OEFL produced 9.5-fold higher p-coumaric acid than the O. Javanica extract (OE). In addition, considering that quinic acid, which is not present in the OE, was produced in the OEFL it was confirmed that chlorogenic acid was decomposed into quinic acid by bioconversion. In the in vivo experiment using Sprague-Dawley rats, the OEFL and p-coumaric acid diets reduced blood ethanol, acetaldehyde, GPT, and ALP concentrations, increasing blood albumin concentrations compared to ethanol-administered groups, demonstrating that OEFL and p-coumaric acid, the main substance in the OEFL, improved ethanol-induced liver damage. Furthermore, the OEFL and its main bioactive substance, p-coumaric acid, alleviated liver fibrosis by downregulating TGF-β, SMAD-2, SMAD-4, α-SMA, and upregulating MMP-1. Therefore, OEFL is expected to be used as a functional food or pharmaceutical material as it has been confirmed to effectively relieve hangovers, prevent liver damage, and delay liver fibrosis in ethanol-induced liver damages.